Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.50 |
| ▸ | RELA | Q04206 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198251 | 0.86 | EED (0.42) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL8979214 | 0.76 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL5698473 | 0.76 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL15466969 | 0.75 | CASP6 (0.54) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL29985725 | 0.74 | ALDH1A1 (0.51) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL7126729 | 0.74 | ALDH1A1 (0.51) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL9205299 | 0.74 | L3MBTL1 (0.41) | NPC1RAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL20900738 | 0.72 | MEN1 (0.48) | SMN1; SMN2NFKB1ALDH1A1MEN1KMT2A | |
| SCHEMBL7785220 | 0.72 | ALDH1A1 (0.44) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL6216654 | 0.72 | NOTUM (0.47) | SMN1; SMN2ALDH1A1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114560859-A | Indoloquinoline derivative and preparation method and application thereof | 华中师范大学 | 2022-05-31 | — | — | CN | disclosed |
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| CN-101827848-B | 2- [ (2- { phenylamino } -1H-pyrrolo [2,3-d ] pyrimidin-4-yl) amino ] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC | 2012-11-07 | — | — | CN | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| CN-101827848-A | 2- [ (2- { phenylamino } -1H-pyrrolo [2,3-d ] pyrimidin-4-yl) amino ] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | SMITHKLINE BEECHAM CORP | 2010-09-08 | — | — | CN | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| EP-2188292-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2010045451-A1 | PYRROLOPYRIMIDINE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| US-4496492-A | Substituted phenylalkyl compounds | THE UPJOHN COMPANY (US) | 1985-01-29 | — | — | US | disclosed |
| US-4431820-A | BACTERICIDES; ANTIBIOTICS | THE UPJOHN COMPANY (US) | 1984-02-14 | — | — | US | disclosed |
| US-4424365-A | 1,2,8,8a-Cyclopropa c!benzo 1,2,-b:-4,3-b'!dipyrrol-4(5H)-ones | THE UPJOHN COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| US-4423229-A | Composition of matter and process | THE UPJOHN COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4423230-A | REACTING A 5-HYDROXY BENZO(1,2-B: 3,4-B')DIPYRROLE WITH TRIPHENYLPHOSPHINE AND CARBONTETRAHALIDE OR N-IODOSUCCINIMIDE | THE UPJOHN COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4423228-A | CYCLIZATION OF ALCOHOL, TRIPHENYLPHOSPHINE, CARBON TETRAHALIDE | THE UPJOHN COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| US-4413132-A | Antibiotic CC-1065 indoline intermediates | THE UPJOHN COMPANY (US) | 1983-11-01 | — | — | US | disclosed |
| US-4400518-A | Composition of matter and process | THE UPJOHN COMPANY (US) | 1983-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | NPC1 4404/4885RAB9A 2910/4885SMN1; SMN2 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.